BABA vs BBW

The Advanced Deterministic Scorecard reveals a mixed financial profile for Alibaba (BABA), with a weak Piotroski F-Score of 4/9 indicating suboptimal financial health, and no available Altman Z-Score limiting distress risk assessment. While valuation metrics appear favorable relative to peers—especially a Price/Sales of 0.41 and Forward P/E of 19.50—earnings growth is sharply negative (YoY EPS down 71%), and recent quarterly beats have reversed into consistent misses over the last four quarters. Strong insider sentiment and a bullish analyst consensus (strong_buy) contrast with deteriorating profitability and weak technical trends (10/100). The stock trades significantly above the Graham Number ($102.68) and intrinsic value estimate ($51.38), suggesting overvaluation unless growth rebounds materially.

BBW's deterministic health scores signal significant concern: the Piotroski F-Score of 2/9 indicates weak financial health, with minimal positive signals across operational efficiency and profitability sustainability. While the Graham Number ($34.11) and intrinsic value ($30.31) suggest undervaluation, the current price of $40.91 trades at a premium, especially given deteriorating earnings growth (YoY -22.1%) and a recent 6-month price decline of 44.3%. Insider selling totaling $4.69M over six months, including a large sale by the CEO, reinforces bearish sentiment. Despite strong historical earnings surprises and high ROE, the company's growth stagnation and declining profitability undermine long-term confidence.